{
    "clinical_study": {
        "@rank": "166390", 
        "acronym": "PKVH PART II", 
        "arm_group": [
            {
                "arm_group_label": "Valsartan 320 mg alone", 
                "arm_group_type": "Other", 
                "description": "Valsartan alone"
            }, 
            {
                "arm_group_label": "Hydrochlorothiazide 25 mg alone", 
                "arm_group_type": "Other", 
                "description": "Hydrochlorothiazide alone"
            }, 
            {
                "arm_group_label": "Valsartan 320 mg + Hydrochlorothiazide 25 mg", 
                "arm_group_type": "Other", 
                "description": "Concomitant administration of valsartan 320 mg + Hydrochlorothiazide 25 mg"
            }, 
            {
                "arm_group_label": "Valsartan / Hydrochlorothiazide 320 mg/25mg", 
                "arm_group_type": "Other", 
                "description": "Fixed dose combination of valsartan 320 mg + Hydrochlorothiazide 25 mg"
            }
        ], 
        "brief_summary": {
            "textblock": "This study was conducted to compare the rate and extent of absorption of valsartan and\n      hydrochlorothiazide. To maximize the possibility of finding drug-drug interactions, the dose\n      of valsartan and hydrochlorothiazide was doubled (320 mg of VAL and 25 mg of HCT)."
        }, 
        "brief_title": "Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide (Double Doses)", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Normotensive Participants", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  At least 18 years old and not more than 45 healthy male volunteers\n\n          -  Actual weight no more than \u00b1 30% from ideal body weight based on sex, height, and\n             body frame\n\n          -  Who had passed all the screening parameters\n\n          -  Free of any drug exposure known to interfere with the pharmacokinetics or assay of\n             fexofenadine for at least 10 days prior to the study\n\n          -  Who had to be able to communicate effectively with study personnel, be literate, and\n             able to give consent.\n\n        Exclusion Criteria:\n\n          -  A clinically significant abnormal physical exam, medical history, or laboratory\n             studies\n\n          -  If they showed a sitting SBP of >140 or <100 mmHg, DBP > 90 or <60mm Hg, or a pulse\n             rate of > 95 or < 50 beats/min at screening\n\n          -  A history of serious intolerance, allergy, or sensitivity to fexofenadine\n\n          -  The use of any prescription drug within the previous month or use of any\n             over-the-counter medication (with the exception of acetaminophen) within the past 14\n             days\n\n          -  A history of blood dyscrasias\n\n          -  A history of alcohol or drug abuse within the past year\n\n          -  Donation of blood during the 8 weeks prior to the study or plans to donate blood\n             during or within 8 weeks of completing the study\n\n          -  Unable to tolerate vein puncture and multiple blood samplings\n\n          -  Any surgical/medical condition that might alter drug absorption, distribution,\n             metabolism, or excretion\n\n          -  Cannot follow instructions, in the opinion of the investigator."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01767298", 
            "org_study_id": "PPT1 PART II"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Valsartan 320 mg + Hydrochlorothiazide 25 mg", 
                    "Valsartan / Hydrochlorothiazide 320 mg/25mg"
                ], 
                "description": "Co-administration or fixed dose combination", 
                "intervention_name": "Valsartan/Hydrochlorothiazide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Valsartan 320 mg alone", 
                "description": "Valsartan alone", 
                "intervention_name": "Valsartan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Hydrochlorothiazide 25 mg alone", 
                "description": "Hydrochlorothiazide alone", 
                "intervention_name": "Hydrochlorothiazide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Hydrochlorothiazide", 
                "Valsartan"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Fixed dose combination", 
            "Pharmacokinetics", 
            "Valsartan", 
            "Hydrochlorothiazide"
        ], 
        "lastchanged_date": "January 10, 2013", 
        "number_of_arms": "4", 
        "official_title": "Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide: An Open-Label, Randomized, Four-Period Crossover Study in Healthy Egyptian Male Volunteers (PART II)", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Egypt: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Tolerability was assessed based on changes in vital signs (temperature, blood pressure, pulse, and heart rate), measured before dosing in each period and approximately every 4 hours thereafter, and laboratory tests (hematology, biochemistry, liver function, and urinalysis), and performed at baseline and at the end of the study. In addition, a physician questioned volunteers about any adverse events occurring during the study, addressed them as necessary, and recorded them on the appropriate form. This physician was not blinded to treatment, but had no involvement in the study.", 
            "measure": "Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "Participants will be followed for the duration of study, an expected average of 6 weeks."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01767298"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Damanhour University", 
            "investigator_full_name": "Sally Helmy, PhD, CPHQ", 
            "investigator_title": "Lecturer of Pharmaceutics, Faculty of Pharmacy", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Damanhour University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Damanhour University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}